Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$80.89M+2596.33%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Raul R. Rodriguez
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 173
- Beta
- 1.24
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 4.58
Financials
Revenue
$80.89M+2596.3%Net Income
$13.19MEBITDA
$19.46MFree Cash Flow
$34.56MEPS (diluted)
$0.65Shares Outstanding (diluted)
20.44M+106.5%Operating Expenses
$53.00MCash & Debt
$99.31MReturn of Capital
$1.02MRevenue by Segment (annual)
$216.30MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $294.28M | $367.02M | $20.40 |
| 2024 | $179.28M | $17.48M | $0.99 |
| 2023 | $116.88M | $-25.09M | $-1.44 |
| 2022 | $120.24M | $-58.57M | $-3.40 |
| 2021 | $149.24M | $-17.91M | $-1.10 |
| 2020 | $108.62M | $-29.74M | $-1.80 |
| 2019 | $59.29M | $-66.55M | $-4.00 |
| 2018 | $44.51M | $-70.48M | $-4.40 |
| 2017 | $4.48M | $-77.99M | $-6.17 |
| 2016 | $20.38M | $-69.22M | $-7.33 |
| 2015 | $28.89M | $-51.46M | $-5.82 |
| 2014 | $8.25M | $-90.91M | $-10.37 |
| 2013 | $7.15M | $-89.03M | $-10.20 |
| 2012 | $2.25M | $-98.84M | $-6.14 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $29.98
- Implied price
- $539.67
- Return from $41.19
- 67.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $268.31 — today's price is already 84.6% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 40.0% | 46.4% | 51.8% | 56.6% | 60.8% |
| 3.0% | 47.1% | 53.8% | 59.5% | 64.5% | 69.0% |
| 8.0% | 54.3% | 61.3% | 67.3% | 72.5% | 77.2% |
| 13.0% | 61.4% | 68.8% | 75.0% | 80.5% | 85.4% |
| 18.0% | 68.5% | 76.2% | 82.8% | 88.5% | 93.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (10)
- Newsmarketbeat.com·16d ago·Neutral
Rigel Pharmaceuticals Q3 Earnings Call Highlights Rigel Pharmaceuticals NASDAQ: RIGL reported record quarterly product sales in the third quarter of 2026, helped by the launch of breast cancer treatment VEPPANU, while net income declined as spending on research and commercialization increased.
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2026 Earnings Call Transcript Rigel Pharmaceuticals, Inc. (RIGL) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·17d ago·Negative
Rigel Pharmaceuticals (RIGL) Misses Q3 Earnings Estimates Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.65 per share, missing the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $1.46 per share a year ago.
View source ↗ - Newsprnewswire.com·18d ago·Neutral
…tamatinib disodium hexahydrate) in patients with chronic ITP and wAIHA SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b clinical study of R2891, a potent and selective inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), in patients with lower-risk myelodysplastic syndrome (MDS) who are re…
View source ↗ - Newsprnewswire.com·24d ago·Neutral
Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2026 financial results after market close on Thursday, November 5, 2026.
View source ↗ - Newsseekingalpha.com·31d ago·Neutral
…ond its ITP legacy. VEPPANU's U.S. launch targets a $1B ESR1-mutated breast cancer market, with early metrics excluded from current guidance and valuation multiples. RIGL trades at a 25–39% discount to sector medians on forward P/E and EV/Sales, while base business demonstrates robust double-digit sales growth and high gross margins.
View source ↗ - Newsprnewswire.com·34d ago·Neutral
…e NSCLC and efficacy and safety in RET fusion-positive thyroid cancer SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced analysis of the pooled efficacy and safety data from two clinical trials of GAVRETO® (pralsetinib), ARROW (NCT03037385) and TAPISTRY (NCT04589845), in patients with rearranged during transfection (RET) fusion-positive solid t…
View source ↗ - Newsprnewswire.com·51d ago·Neutral
…unces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4).
View source ↗ - Newsprnewswire.com·81d ago·Neutral
Rigel to Participate in Upcoming September Investor Conferences SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will participate in the following investor conferences in September: Citi's 2026 Biopharma Back to School Conference in New York, NY Rigel will participate in one-on-one mee…
View source ↗ - Newsprnewswire.com·101d ago·Negative
…atment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced VEPPANUTM (vepdegestrant) is now available by prescription in the United States for the treatment of adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 …
View source ↗
Earnings
Tue, Mar 2(in 3 months)
Consensus estimate $1.07 per share
Typical surprise +57.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$0.65 vs $0.87miss
- Tue, Aug 4$0.88 vs $0.09beat
- Tue, May 5$0.44 vs $0.74miss
- Tue, Mar 3$1.14 vs $1.33miss
- Tue, Nov 4$1.46 vs $0.93beat
- Tue, Aug 5$3.28 vs $1.97beat
Estimates and results for RIGL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RIGL officers and directors.
- Bought
- —
- Sold
- $470k
0 trades
7 trades
- Ali-jackson Kamilsold
- Ali-jackson Kamilsold
- Moos Walter Hsold
- Schorno Dean Lsold
- Santos David Asold
- Schorno Dean Lsold
- Santos David Asold
93 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RIGL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
